US 5,371,104 AGrant
Compositions Containing Forskolin
Issue Date:1994-12-06
•3 Claims
Abstract
The invention relates to a process for the solubilzation of forskolin, to the pharmaceutical compositions based on such solubilized forskolin and to the use of these in the treatment of various diseases and disorders and maladies in mammals, including human. Forskolin is 7-beta-acetoxy-8,13-epoxy-1-alpha,6-beta,9-alpha-trihydroxylabd-14-en-11-o ne.
Metadata
Inventor
- Jeffery J. Feigenbaum
Application Information
Application Number:US 1985361
Filing Date:1994-02-18
Priority Date:1989-03-08
Art Unit:125
Classifications
IPC:
A61K 3135
Field of Search:
514453;455
Patent Drawings
This patent does not have any drawings.
Description
BACKGROUND OF THE INVENTION
The invention relates to solubilized forskolin (hereafter CHRL-1 being forskolin in solubilized form as described herein), and to its preparation. It further relates to pharmaceutical compositions containing such solubilized forskolin ingredient (i.e. CHRL-1).
Forskolin is a labdane diterpenoid, obtainable from natural sources by methanol extraction of the roots of coleus forskoli. The chemical name of forskolin is 7-beta-acetoxy-8,13-epoxy-1-alpha,6-beta,9-alpha-trihydroxylabd-14-en-11-o ne. The synthesis of forskolin is reported by S. D. Baltt, B. S., Bhawa, H. Dornauer, N. J. de Souza, and H. W. Fehlhaber, Tetrahedron Letters (1977); and by N. J. de Souza, A. N. Dohadwalla, and J. Reden Med. Revs., vol. 3 (1983) pp. 201-219 and references cited therein. One commercial source of forskolin is Sigma Pharmaceutical Co., St. Louis, Mo. I believe that forskolin has not previously been used in vivo in the solubilized form described hereinafter.
SUMMARY OF THE INVENTION
I have found that forskolin is very soluble in dimethylacetate (DMA), and that this solution can be diluted with distilled water or saline for pharmaceutical use in the presence of a further additive, such as a non-ionic surfactant. A solution can also be made up with this solvent and an edible oil, for per os application; and also in non-edible oils. A further effective solvent is dimethyl-sulfoxide (DMSO), used together with a further additive such as a surfactant, as set out in detail hereinafter. A solution of forskolin can also be made up with DMSO and an edible oil for per os application, and also in non-edible oils for its administration by other routes.
The invention also relates to potent and long-lasting analgetic compositions which contain CHRL-1, and to pharmaceutical compositions containing CHRL-1 which are long acting and potent in counteracting the respiratory depression, hypothermia and addiction induced by morphine and by related narcotic compounds. Moreover, CHRL-1 has significant anti-depressant activity. CHRL-1 is also very active in inhibiting the psychotropic effects of high doses of delta.sup.1 -tetrahydrocannabinol (THC) and other cannabinoids contained within cannabis. Finally, the invention relates to compositions containing CHRL-1 which counteract the neuronal toxicity (and other toxicity), the behavioral aberrancies and the lethal effects induced by N-methyl-D-aspartate (NMDA) and resulting from NMDA receptor stimulation. Thus, my invention is useful in the treatment of various diseases and disorders and maladies in mammals, including humans.
DETAILED DESCRIPTION OF THE INVENTION
CHRL-1 can be prepared from the solvents listed above in the Summary or from other solvents. Amongst other possible solvents for forskolin there may be mentioned dipropylene glycol, ethylene glycol, formamide, dimethyl formamide, ethylene chloride, diethanolamine, triethanolamine, ethyl acetate, ethylmethoxyethanol, methyl chloride, methylene chloride, and dimethylamine. The limiting factor is one of physiological acceptability and possible toxicity. Considering these aspects, the first six members of this list are acceptable and can be used as solvents in the present invention. Such solvents can be used together with diacetylated monoglyglcerides, dihydric alcohols including ethylene glycol, diethylene glycol, methylene glycol, propylene and dipropylene glycol; glyceryl mono-oleate, glyceryl monostearate, mono- or diglycerides; sucrose esters, as well as glycol, glycerol or polyoxyethelene esters; propylene glycol stearate, ethers (macrogol, macrogol lauryl, polyoxyl 20 cetostearyl and polyoxyoxyl 10 oleyl), octoxinols, poloxamers, polyvinyl alcohol, quillaia, saponin polysorbates, 20, 40, 60, 65, 80 and 85); and the sorbitans monolaurate, mono-oleate, monopalmitate, monostearate, sesquiolate trioleate, tristearate; and sorbitan derivatives, all of which may be used by themselves or together with DMA or DMSO.
The preferred systems are those of DMSO with a suitable surfactant or DMA with such surfactant.
When DMSO is used, the solubilization is effected by contacting a certain quantity of forskolin and the solvent, vortexing at high speed so as to dissolve the forskolin and adding a suitable active agent such as Emulphor (polyoxyethylated vegetable oil); vortexing again until a clear solution is obtained, and diluting same with a desired quantity of water or saline.
For example, 50 mg forskolin is mixed with 0.4 mn DMSO, vortexed at high speed for 2 minutes; 0.4 ml Emulphor or another non-ionic surfactant is added followed by further vortexing until a clear solution is obtained, with 1.7 ml water or saline added to result in a clear solution containing about 20 mg/ml containing about 16% DMSO and about 16% Emulphor.
As a further example, 2.5-4.5 mg. forskolin is added to 0.5 mn of DMA in a small (4 ml) vial, completely covering all of the drug with the solvent. When the drug is completely dissolved, 0.10 ml of a non-ionic surfactant is added (preferably Tween 20, a polyoxyethylene sorbitan monooleate or Emulphor El-620, a polyoxyethylated vegetable oil). Heating is unnecessary. The forskolin, dissolved in DMA, is thoroughly integrated into the surfactant by turning the vial on its side and rotating slowly, allowing the DMA-containing forskolin and the surfactant to mix together while coating the sides of the vial. The rotation should take 3-3.5 min. Following this, dilution is effected as required with distilled water or saline followed by vortexing at maximum speed for 2-3 min.(The same technique for integrating the forskolin into the surfactant may also be employed when using DMSO as a solvent).
The solubilized form of forskolin (i.e. CHRL-1) results in a stimulation of adenylate cyclase activity at dosages 10 to more than 20 times lower than that of the drug in suspension, without any apparent side effects in animals administered 1 .mu.g/kg to 1 mg/kg of CHRL-1 in vivo. When, in contrast, forskolin is administered in vivo om the form of a suspension, the dosage required to stimulate adenylate cyclase is about 20 mg/kg, with behavioral disturbances resulting, including either sedation, or head twitches and motor stereotypies (q.v. Wachtel et al., Neurosci. Lett. 76: 191-196 (1987).
CHRL-1 in doses in 1 .mu.g/kg provides very potent analgesia in both inbred (C-57/B-1) and outbred (Sabra) mice, as well as in rats (Sabra; an outbred strain). The analgesia is equivalent to 10-20 mg/kg of morphine but unlike the latter, is not accompanied by sedation, or marked hypothermia and respiratory depression. Moreover, unlike morphine induced analgesia, the antinociceptive activity of CHRL-1 lasts over 24 hours, and is characterized by very low tolerance and addiction potential. These effects are summarized in Tables 1 and 2 below.
The same doses of CHRL-1 also completely reverse the respiratory depression induced by a high (25 mg/kg) dose of morphine within 15-20 min. of the administration of CHRL-1; with respiration increasing from about 65% of normal, to slightly over 100% of normal. Moreover, pretreatment with a 50 .mu.g/kg dose of CHRL-1 48 h. prior to the same dose of morphine (25 mg/kg) was seen to completely protect rats so injected from undergoing any significant change in respiration (see Tables 1.1.1. and 1.1.2. below). The same doses of CHRL-1 1 .mu.g/kg to 150 .mu.g/kg also significantly reversed the hypothermia induced by morphine (25.0 mg/kg) within 15 minutes, from about -2.degree. C. to -0.8.degree. C. (the highest dose of 150 .mu.g/kg being less effective than 1 and 50 .mu.g/kg). The hypothermia was completely reversed by all doses of CHRL-1 administered within 1 hr. of its administration at a time when control animals receiving only morphine had a core body temperature 2.2.degree. C. below normal (see Table 2 below).
The same doses of CHRL-1 (1 .mu.g/kg to 500 .mu.g/kg) also markedly inhibited the `dispair` of rats in a forced swimming paradigm of anti-depressant activity by as much as 50% relative to control (See Table 3 below). The same doses of CHRL-1 (1 and 50 .mu.g/kg) also significantly inhibited the tremor, seizure and death induced by N-methyl-D-Aspartate (115 mg/kg) with the lower dose of CHRL-1 being totally effective (see Table 4 below). The same doses of CHRL-1 (1 .mu.g/kg) induced a nearly complete supression of naloxone-precipitated jumping in mice addicted to morphine by pellet implantation (75 mg. morphine over 72 h.), in a small group of animals.
A 50 .mu.g/kg dose of CHRL-1 also completely reversed the psychotropic effects induced by an extremely high (25 mg/kg) dose of .DELTA..sup.1 -tetrahydrocannabinol in both inbred (C-57/B-1) and outbred (Sabra) mice, as measured by the Ring Test of Pertwee. CHRL-1 reduced the .DELTA..sup.1 -THC elicited elevations of the psychotropic index by up to 58-59%, to control levels (see Table 4). CHRL-1 solution stored at ambient temperature for 6 months was used for repeat tests and compared with fresh solutions. No reduction in activity was observed. It should be noted that all of the activities of CHRL-1 discussed above and summarized in the tables below were observed following the administration of a solution prepared with DMSO and emulphor. This solution is clear and essentially odorless, and has a pH of . when made up to a concentration of 50 .mu.g/ml. The solution freezes at 0.degree. C. and has a boiling point of about 94.degree. C. At. 42.degree. C. it is stable and can be stored at room temperature for at least one month without refrigeration.
As it may be seen from Tables A and B below, the doses of CHRL-1 at which optimal activity is seen (i.e. 1 and 50 .mu.g/kg) contain about 0.0009% and 0.047% DMSO respectively, and 0.002 and 0.06DMA respectively. DMSO is currently being used as a vehicle for drugs such as idoxuridine and is available for human use as a 50% solution in the USA (as Rimso-50;.RTM. Research Industries Corp.) and as a 70% solution in Canada (as Kemsol.RTM., Horner). The safety of DMSO as a solvent or as a drug in its own right for human use is discussed by Mason (in Dimethyl Sulfoxide, Vol. 1, Marcel Dekker, Inc., New York, 1971) and by Swanson (Rev. Clin. Basic Pharmacol. 5: 1-33 (1985). DMA is currently used as a solvent in drugs and other pharmaceutical products (Martindale's, 28.sup.th Ed., 1982) and is less toxic than dimethylformamide (Ibid.), which Bristol Myers has included in one of its patents for cis-platinum.
TABLES
The Tables A and B below give the volume and % of water, solvent and surfactant for various solutions of CHRL-1. In each solution, the absolute amount of solvent (DMSO or DMA) and surfactant remains constant.
The TABLES 1 to 6 DIVERSE ACTIVITY OF CHRL-1IN VIVO
Claims
I claim:
1. A method for providing analgesia in a mammal, comprising the step of: administering to said mammal a dose of between about 0.001 to about 1.0 mg/kg/day of a composition essentially of forskokin solubilized in dimethyl sulfoxide and a surface-active agent.
2. The method of claim 1, wherein said composition is administered in an amount effective to provide a dose of forskolin from about 0.001 to about 0.005 mg/kg/day.
3. The method of claim 1, wherein said composition is administered at a dose of from about 0.1 to about 1.0 mg/kg/day.
Patent Citations (7)
Non-Patent Literature (3)
- Huang et al., "Inhibition of Forskolin-Activated Adenylate Cyclase by Ethanol and Other Solvents," J. Cyclic Nucleotide Res., 8(6):385-394 (1982).
- Chemical Abstracts: vol. 110 (25) 225312(t) (1989).
- Chemical Abstracts: vol. 111(14) 120890(x) (1990).